Submission of Financial result for the quarter and half year ended 30.09.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Ltd resubmitted a clear copy of its unaudited financial results for the quarter and half year ended September 30, 2025, after BSE flagged legibility issues in the earlier PDF. On a standalone basis, Q2 FY26 revenue surged to Rs. 3,156.37 lakhs from Rs. 576.95 lakhs in Q2 FY25 (over 4x growth), lifting H1 FY26 revenue to Rs. 4,367.68 lakhs versus Rs. 1,107.24 lakhs in H1 FY25. Standalone profit after tax for H1 FY26 was Rs. 237.51 lakhs, up about 50% from Rs. 158.64 lakhs a year ago. On a consolidated basis, H1 FY26 profit collapsed to just Rs. 3.90 lakhs (from Rs. 103.22 lakhs) because the newly acquired subsidiary Derren Healthcare (70% stake completed July 25, 2025) contributed a loss of Rs. 171.60 lakhs since acquisition. The Q2 FY26 consolidated result swung to a loss of Rs. 117.62 lakhs, with segment data showing Derren at a Rs. 165.35 lakh segment loss. New auditor Bilimoria Mehta & Co. signed off with an unmodified review conclusion, noting reliance on the erstwhile auditor's report for the Q1 FY26 figures.
Shareholders will note very strong top-line growth on a standalone basis and a clear margin expansion, but the consolidated picture is weakened by the freshly consolidated Derren Healthcare subsidiary which is loss-making. The mid-year auditor change and the change in accounting policy (reclassifying certain shares from inventory to investments at fair value) are items investors should monitor, though neither triggered any qualifications from the auditor.